Today is International Women’s Day. Please join me in celebrating some of the women who have made significant contributions to our understanding of pancreatic cancer through PanCAN Research Grants.
International Women’s Day Read More »
A few years ago, Luke Timmerman of Xconomy wrote about the 21 Red Flags in biotech investing and Sally Church of the Pharmastrategy Blog wrote a related post on Red Flags in clinical trials and cancer research. Here are a few additions of my own that I’d like to add to those lists. Context is
Red Flags in Drug Discovery Read More »
Last year the news was all abuzz with new evidence that was uncovered by amateur investigators looking into the most infamous hijacker in aviation history, a man known only as DB Cooper. The investigators found traces of material on his tie that was connected to Boeing’s SST development. But the story leaves more unanswered questions
DB Cooper Stories in Cancer Read More »
Storytelling is an integral part of the scientific process. Whether it’s sharing information with your colleagues, or sharing it with the wider community.
Pipeline Stories: The Importance of Storytelling In Research Read More »
A recent discovery may hold the key to understanding cachexia, a common co-morbidity in cancer patients.
Beyond the genomic complexity of the disease, we’ve begun to examine the effect of the microbiome on pancreatic cancer. In a recent paper in Science, “Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine” [Geller et al] reported that 76% of pancreatic cancer patients in their study (n=113) had gammaproteobacteria in
Pancreatic Cancer and the Microbiome Read More »
In the third part of this series on pancreatic cancer, we’ll take a look at recent developments in identifying subtypes of pancreatic cancer and its potential impact on the lives of pancreatic cancer patients. Twenty-one years ago, we had identified some of the histologically distinct types of pancreatic cancer. These neoplastic tissue types included: PanINs
Subtypes of Pancreatic Cancer Read More »
In the second part of this series on pancreatic cancer, we’ll look at the changes in our understanding of the role of familial genetics in pancreatic cancer, and how that new understanding holds promise for new therapeutics. In the mid-1970s doctors began reporting cases of familial pancreatic cancer, where multiple first-degree relatives had presented with
The Genetics of Pancreatic Cancer Read More »
A look at our changing understanding of the genetics of pancreatic cancer, and the genomic technologies that helped us gain that understanding over the past 21 years.
Remember, Remember… Read More »
At the front end of most drug discovery programs lies a step called Target Identification, and a few months ago I sat down with a colleague to discuss their approach to target identification. In particular, “how do you characterize a target”? I was surprised at how much that process can vary from company to company. As
Drug Target Identification: And then a miracle occurs Read More »
